Xolair Qui Tam Dismissal Affirmed By 1st Circuit, But State Claims Remanded
BOSTON — The First Circuit U.S. Court of Appeals on June 17 affirmed dismissal without prejudice of two relators’ claims that Novartis Pharmaceuticals Corp. and Genentech Inc. marketed the asthma drug...To view the full article, register now.
Already a subscriber? Click here to view full article